BCR-ABL1 transcript levels at 4 weeks have prognostic significance for time-specific responses and for predicting survival in chronic-phase chronic myeloid leukemia patients treated with various tyrosine kinase inhibitors

BCR-ABL1 transcript levels at 4 weeks have prognostic significance for time-specific responses and for predicting survival in chronic-phase chronic myeloid leukemia patients treated with various tyrosine kinase inhibitors

Item

http://www.wikidata.org/entity/Q58778554

Q58778554

about

BCR-ABL1 transcript levels at 4 weeks have prognostic significance for time-specific responses and for predicting survival in chronic-phase chronic myeloid leukemia patients treated with various tyrosine kinase inhibitors

Item

http://www.wikidata.org/entity/Q58778554

description

article

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована в жовтні 2018

@uk

name

BCR-ABL1 transcript levels at ...... ous tyrosine kinase inhibitors

@en

BCR-ABL1 transcript levels at ...... ous tyrosine kinase inhibitors

@nl

type

Item

label

BCR-ABL1 transcript levels at ...... ous tyrosine kinase inhibitors

@en

BCR-ABL1 transcript levels at ...... ous tyrosine kinase inhibitors

@nl

prefLabel

BCR-ABL1 transcript levels at ...... ous tyrosine kinase inhibitors

@en

BCR-ABL1 transcript levels at ...... ous tyrosine kinase inhibitors

@nl

P1476

BCR-ABL1 transcript levels at ...... ous tyrosine kinase inhibitors

@en

P2093

Dong-Wook Kim

http://www.w3.org/2001/XMLSchema#string

Eun-Jung Jang

http://www.w3.org/2001/XMLSchema#string

Hayeon Noh

http://www.w3.org/2001/XMLSchema#string

Jangik I Lee

http://www.w3.org/2001/XMLSchema#string

Ji-Hyung Suh

http://www.w3.org/2001/XMLSchema#string

Ki-Hoon Kang

http://www.w3.org/2001/XMLSchema#string

Kyung-Mi Kee

http://www.w3.org/2001/XMLSchema#string

Mi-Young Lee

http://www.w3.org/2001/XMLSchema#string

Seon-Young Yang

http://www.w3.org/2001/XMLSchema#string

Soo Young Choi

http://www.w3.org/2001/XMLSchema#string

P2860

Major molecular response achievement in CML Patients can be predicted by BCR-ABL1/ABL1 or BCR-ABL1/GUS ratio at an earlier time point of follow-up than currently recommended.

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.

Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION).

Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)

Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib

Early BCR-ABL1 Transcript Decline after 1 Month of Tyrosine Kinase Inhibitor Therapy as an Indicator for Treatment Response in Chronic Myeloid Leukemia.

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.

Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities

BCR-ABL1 transcripts (MR4.5) at post-transplant 3 months as an early predictor for long-term outcomes in chronic myeloid leukemia.

Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy

P304

5107-5117

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CAM4.1753

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Hye-Young Song

Sung-Eun Lee

Hea-Lyun Yoo

P577

2018-08-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30171671

http://www.w3.org/2001/XMLSchema#string

P932

6198233

http://www.w3.org/2001/XMLSchema#string

BCR-ABL1 transcript levels at 4 weeks have prognostic significance for time-specific responses and for predicting survival in chronic-phase chronic myeloid leukemia patients treated with various tyrosine kinase inhibitors

about

BCR-ABL1 transcript levels at 4 weeks have prognostic significance for time-specific responses and for predicting survival in chronic-phase chronic myeloid leukemia patients treated with various tyrosine kinase inhibitors

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932